HTML Microdata document

This HTML5 document contains 76 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

Prefix	IRI
n2	http://linked.opendata.cz/resource/drugbank/drug/
dcterms	http://purl.org/dc/terms/
n11	http://linked.opendata.cz/resource/AHFS/
n18	http://linked.opendata.cz/resource/drugbank/company/
n26	http://linked.opendata.cz/resource/mesh/concept/
n29	http://linked.opendata.cz/resource/drugbank/drug/DB01367/identifier/chemspider/
foaf	http://xmlns.com/foaf/0.1/
n12	http://linked.opendata.cz/resource/drugbank/dosage/
n20	http://linked.opendata.cz/resource/drugbank/drug/DB01367/identifier/wikipedia/
n24	http://bio2rdf.org/drugbank:
n17	http://linked.opendata.cz/resource/drugbank/drug/DB01367/identifier/pharmgkb/
adms	http://www.w3.org/ns/adms#
n31	http://linked.opendata.cz/resource/drugbank/drug/DB01367/identifier/pdb/
n27	http://linked.opendata.cz/resource/drugbank/drug/DB01367/identifier/bindingdb/
n19	http://www.rxlist.com/cgi/generic/
n4	http://linked.opendata.cz/resource/drugbank/drug/DB01367/identifier/pubchem-compound/
n13	http://linked.opendata.cz/resource/drugbank/patent/
n22	http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdf	http://www.w3.org/1999/02/22-rdf-syntax-ns#
n28	http://linked.opendata.cz/resource/drugbank/medicinal-product/
n6	http://linked.opendata.cz/ontology/drugbank/
owl	http://www.w3.org/2002/07/owl#
n25	http://linked.opendata.cz/ontology/mesh/
n30	http://linked.opendata.cz/resource/drugbank/drug/DB01367/identifier/pubchem-substance/
n5	http://linked.opendata.cz/resource/drugbank/drug/DB01367/identifier/kegg-drug/
n15	http://www.drugs.com/cdi/
n9	http://linked.opendata.cz/resource/drugbank/drug/DB01367/identifier/drugbank/
n7	http://linked.opendata.cz/resource/drugbank/property/
xsdh	http://www.w3.org/2001/XMLSchema#
n8	http://linked.opendata.cz/resource/drugbank/drug/DB01367/identifier/national-drug-code-directory/
n16	http://linked.opendata.cz/resource/atc/
n10	http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item: n2:DB01367
rdf:type: n6:Drug
n6:description: Rasagiline is an irreversible inhibitor of monoamine oxidase and is used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases.
n6:dosage: n12:271B4308-363D-11E5-9242-09173F13E4C5 n12:271B4309-363D-11E5-9242-09173F13E4C5 n12:271B430A-363D-11E5-9242-09173F13E4C5 n12:271B430B-363D-11E5-9242-09173F13E4C5
n6:generalReferences: # Weinreb O, Amit T, Bar-Am O, Youdim MB: RASAGILINE; A NOVEL ANTI-PARKINSONIAN MONOAMINE OXIDASE-B INHIBITOR WITH NEUROPROTECTIVE ACTIVITY. Prog Neurobiol. 2010 Jun 19. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20600573 # Leegwater-Kim J, Bortan E: The role of rasagiline in the treatment of Parkinson's disease. Clin Interv Aging. 2010 May 25;5:149-56. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20517484 # Chen JJ, Swope DM, Dashtipour K: Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease. Clin Ther. 2007 Sep;29(9):1825-49. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18035186
n6:group: approved
n6:halfLife: Rasagiline has a mean steady-state half life of 3 hours but there is no correlation of pharmacokinetics with its pharmacological effect because of its irreversible inhibition of MAO-B.
n6:indication: For the treatment of the signs and symptoms of idiopathic Parkinsons disease as initial monotherapy and as adjunct therapy to levodopa.
owl:sameAs: n22:DB01367 n24:DB01367
dcterms:title: Rasagiline
adms:identifier: n4:3052776 n5:D02562 n8:68546-142-56 n9:DB01367 n17:PA164764584 n20:Rasagiline n27:10989 n29:2314553 n30:46506045 n31:RAS
n6:mechanismOfAction: The precise mechanisms of action of rasagiline is unknown. One mechanism is believed to be related to its MAO-B inhibitory activity, which causes an increase in extracellular levels of dopamine in the striatum. The elevated dopamine level and subsequent increased dopaminergic activity are likely to mediate rasagiline's beneficial effects seen in models of dopaminergic motor dysfunction.
n6:packager: n18:271B4305-363D-11E5-9242-09173F13E4C5 n18:271B4304-363D-11E5-9242-09173F13E4C5
n6:patent: n13:5387612 n13:2232310 n13:7572834 n13:2031714
n6:routeOfElimination: Rasagiline undergoes almost complete biotransformation in the liver prior to excretion. Glucuronide conjugation of rasagiline and its metabolites, with subsequent urinary excretion, is the major elimination pathway. After oral administration of 14C-labeled rasagiline, elimination occurred primarily via urine and secondarily via feces (62% of total dose in urine and 7% of total dose in feces over 7 days), with a total calculated recovery of 84% of the dose over a period of 38 days. Less than 1% of rasagiline was excreted as unchanged drug in urine.
n6:synonym: RAS (R)-N-2-Propynyl-1-indanamine (1R)-N-Propargylindan-1-amine (R)-Indan-1-yl-prop-2-ynyl-amine
n6:toxicity: Signs and symptoms of overdosage may include, alone or in combination, any of the following: drowsiness, dizziness, faintness, irritability, hyperactivity, agitation, severe headache, hallucinations, trismus, opisthotonos, convulsions, and coma; rapid and irregular pulse, hypertension, hypotension and vascular collapse; precordial pain, respiratory depression and failure, hyperpyrexia, diaphoresis, and cool, clammy skin.
n6:volumeOfDistribution: * 87 L
n10:hasAHFSCode: n11:28-92-00
n6:foodInteraction: Avoid alcohol and caffeine.
n6:proteinBinding: Plasma protein binding ranges from 88-94% with mean extent of binding of 61-63% to human albumin over the concentration range of 1-100 ng/ml.
n6:synthesisReference: Jeffrey Sterling, David Lerner, Harel Rosen, Leonid Bronov, Dalia Medini-Green, Berta Iosefzon, Tirtsah Berger-Peskin, Ramy Lidor-Hadas, Eliezer Bahar, "Rasagiline formulations and processes for their preparation." U.S. Patent US07598420, issued October 06, 2009.
n25:hasConcept: n26:M0100095
foaf:page: n15:rasagiline.html n19:azilect.htm
n6:IUPAC-Name: n7:271B4310-363D-11E5-9242-09173F13E4C5
n6:InChI: n7:271B4316-363D-11E5-9242-09173F13E4C5
n6:Molecular-Formula: n7:271B4315-363D-11E5-9242-09173F13E4C5
n6:Molecular-Weight: n7:271B4312-363D-11E5-9242-09173F13E4C5
n6:Monoisotopic-Weight: n7:271B4313-363D-11E5-9242-09173F13E4C5
n6:SMILES: n7:271B4314-363D-11E5-9242-09173F13E4C5
n6:Water-Solubility: n7:271B430E-363D-11E5-9242-09173F13E4C5
n6:logP: n7:271B430C-363D-11E5-9242-09173F13E4C5 n7:271B430F-363D-11E5-9242-09173F13E4C5
n6:logS: n7:271B430D-363D-11E5-9242-09173F13E4C5
n10:hasATCCode: n16:N04BD02
n6:H-Bond-Acceptor-Count: n7:271B431C-363D-11E5-9242-09173F13E4C5
n6:H-Bond-Donor-Count: n7:271B431D-363D-11E5-9242-09173F13E4C5
n6:InChIKey: n7:271B4317-363D-11E5-9242-09173F13E4C5
n6:Polar-Surface-Area--PSA-: n7:271B4318-363D-11E5-9242-09173F13E4C5
n6:Polarizability: n7:271B431A-363D-11E5-9242-09173F13E4C5
n6:Refractivity: n7:271B4319-363D-11E5-9242-09173F13E4C5
n6:Rotatable-Bond-Count: n7:271B431B-363D-11E5-9242-09173F13E4C5
n6:absorption: Rasagiline is rapidly absorbed following oral administration. The absolute bioavailability of rasagiline is about 36%.
n6:affectedOrganism: Humans and other mammals
n6:casRegistryNumber: 136236-51-6
n6:category
n6:containedIn: n28:271B4306-363D-11E5-9242-09173F13E4C5 n28:271B4307-363D-11E5-9242-09173F13E4C5
n6:Bioavailability: n7:271B4321-363D-11E5-9242-09173F13E4C5
n6:Ghose-Filter: n7:271B4323-363D-11E5-9242-09173F13E4C5
n6:MDDR-Like-Rule: n7:271B4324-363D-11E5-9242-09173F13E4C5
n6:Number-of-Rings: n7:271B4320-363D-11E5-9242-09173F13E4C5
n6:Physiological-Charge: n7:271B431F-363D-11E5-9242-09173F13E4C5
n6:Rule-of-Five: n7:271B4322-363D-11E5-9242-09173F13E4C5
n6:Traditional-IUPAC-Name: n7:271B4311-363D-11E5-9242-09173F13E4C5
n6:pKa--strongest-basic-: n7:271B431E-363D-11E5-9242-09173F13E4C5